	US 11,813,249 B2
	Combination therapy for treatment of restenosis
Kirk Patrick Seward, Brooklyn, NY (US)
Assigned to Mercator MedSystems, Inc., San Leandro, CA (US)
Filed by Mercator MedSystems, Inc., Emeryville, CA (US)
Filed on Jan. 14, 2021, as Appl. No. 17/149,631.
Application 16/591,467 is a division of application No. 15/990,167, filed on May 25, 2018, granted, now 10,576,063, issued on Mar. 3, 2020.
Application 17/149,631 is a continuation of application No. 16/591,467, filed on Oct. 2, 2019, granted, now 10,925,863.
Claims priority of provisional application 62/624,528, filed on Jan. 31, 2018.
Claims priority of provisional application 62/511,797, filed on May 26, 2017.
Prior Publication US 2021/0236472 A1, Aug. 5, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/436 (2006.01); A61P 9/14 (2006.01); A61P 9/04 (2006.01); A61K 9/00 (2006.01); A61P 9/10 (2006.01); A61K 31/573 (2006.01)

CPC A61K 31/436 (2013.01) [A61K 9/0019 (2013.01); A61P 9/04 (2018.01); A61P 9/10 (2018.01); A61P 9/14 (2018.01); A61K 31/573 (2013.01); A61K 2300/00 (2013.01)]

34 Claims

1. A pharmaceutical composition comprising temsirolimus and a glucocorticoid, or their pharmaceutically acceptable salts thereof,

wherein the composition is in an injectable dosage form, and

wherein the therapeutically effective amount of glucocorticoid is about 0.8 mg to 8 mg per cm of longitudinal length of a disease site in a blood vessel.